On July 27, 2026, the Emirates Drug Establishment (EDE) published Federal Decree-Law No. (27) of 2026 on the UAE Good Pharmacovigilance Practice Guideline for Medical Products, listing it on the federal legislations register with a publication date of Monday, 27 July 2026. The instrument establishes the requirements and framework for pharmacovigilance of medical products marketed in the United Arab Emirates, filling the standalone standards gap that practitioners had flagged since the overarching pharmaceutical law took effect.
For marketing authorisation holders (MAHs), the decree-law is the awaited detailed pharmacovigilance instrument that the EDE was expected to issue separately from the omnibus implementing regulations of Federal Decree-Law No. 38 of 2024. It moves UAE pharmacovigilance from a general obligation under the parent law to a dedicated Good Pharmacovigilance Practice (GVP) regime, with direct consequences for QPPVs, safety system owners and adverse-event reporting workflows.
What does Decree-Law 27/2026 change for marketing authorisation holders?
The decree-law establishes a structured GVP framework for medical products, setting the requirements that MAHs must meet across the pharmacovigilance lifecycle. It codifies the practice standard that governs how companies detect, assess, understand and prevent adverse effects of medicines placed on the UAE market, aligning the federal layer with the international GVP architecture already familiar to EMA- and ICH-aligned firms.
Practitioners should read the instrument as the UAE standalone pharmacovigilance practice standard, distinct from the procedural rules expected under the implementing regulations of FDL 38/2024. Where the parent law set the obligation to maintain a pharmacovigilance system, this decree-law sets the practice detail that defines what a compliant system looks like.
Who must comply, and by when?
The framework applies to pharmaceutical and medical device MAHs operating in or selling into the UAE, together with the UAE-resident qualified persons responsible for pharmacovigilance (QPPVs), PV teams, local distributors and importers that handle medical products under EDE supervision. Non-UAE MAHs whose products reach the UAE market through local agents are within scope, not only firms established in the country.
The decree-law is published and listed as federal law on the EDE register as of July 27, 2026. Companies should treat the publication date as the start of the alignment window, pending any effective-date or transitional provisions stated in the instrument itself. Until the EDE issues explicit grace terms, PV leads should assume the practice standard applies to their UAE portfolio and close the gap now rather than wait for enforcement.
How does this fit with Federal Decree-Law 38/2024?
The new instrument sits downstream of Federal Decree-Law No. (38) of 2024 on Medical Products, Pharmacists and Pharmaceutical Establishments, the overarching UAE pharmaceutical law in force since January 2, 2025, whose one-year grace period expired on January 2, 2026. FDL 38/2024 established the obligation to operate a pharmacovigilance system and empowered the EDE to set detailed standards; Decree-Law 27/2026 is the standalone GVP standard that gives that obligation operational teeth.
| Instrument | Layer | Role |
|---|---|---|
| Federal Decree-Law 38/2024 | Parent pharmaceutical law | Sets the PV system obligation and EDE mandate, in force since 2 January 2025 |
| Implementing Regulations of FDL 38/2024 | Omnibus procedural rules | Still pending at the EDE; will cover fast-track MA, transfers, compassionate use, track-and-trace |
| Federal Decree-Law 27/2026 | Standalone GVP standard | Defines good pharmacovigilance practice for medical products, published 27 July 2026 |
The standalone track means companies should not wait for the omnibus implementing regulations to begin PV alignment: the GVP standard is now an independent compliance target.
What should PV and regulatory affairs teams do now?
PV and regulatory affairs leads should treat July 27, 2026 as the trigger date for a structured gap assessment against the new GVP standard. The practical steps are concrete and should start immediately, because the parent law grace period has already lapsed and the EDE now has a dedicated practice instrument to enforce.
- Read the instrument in full: pull Decree-Law 27/2026 from the EDE legislations register and confirm any effective-date, transitional or scope provisions it carries.
- Audit your PV system: map your pharmacovigilance system master file, QPPV arrangements, signal management and adverse-event reporting against the new practice standard.
- Confirm UAE-resident QPPV coverage: verify that the responsible person and the reporting channel meet the federal requirement for every product on the UAE market.
- Brief the local agent and distributors: ensure importers and local representatives understand the reporting obligations that now attach to their role.
- Track the omnibus implementing regulations: the pending executive regulations of FDL 38/2024 will add procedural detail on top of this GVP standard, so keep both instruments on the monitoring list.
Continuous, per-jurisdiction real-time monitoring surfaces this kind of change the moment it publishes on the official register, before trade-press commentary catches up.
Take advantage of this real-time watch
Next steps: confirm applicability to your UAE portfolio, document the gap assessment against Decree-Law 27/2026, and brief your QPPV and regulatory affairs team on the new practice standard before the EDE begins enforcement. Obsidian tracks this instrument and the pending FDL 38/2024 implementing regulations as they evolve.
